Effect of CYP2C19 Genotype on Inhibition of Platelet Aggregation in Hemodialysis Patients With Coronary Artery Disease

被引：0
|
作者：
Waseda, Katsuhisa
Saka, Yuki
Takashima, Hiroaki
Kurita, Akiyoshi
Ando, Hirohiko
Sakurai, Shinichiro
Suzuki, Akihiro
Sawada, Hiroaki
Sato, Shigeko
Nishikawa, Yoshinori
Amano, Tetsuya
机构：
来源：
CIRCULATION | 2016年 / 134卷
关键词：
Antiplatelet drugs; Prasugrel; Clopidogrel; Renal function; Genetics;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
14237
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effect of CYP2C19 Genotype on Inhibition of Platelet Aggregation in Hemodialysis Patients With Coronary Artery Disease
    Waseda, Katsuhisa
    Saka, Yuki
    Takashima, Hiroaki
    Kurita, Akiyoshi
    Ando, Hirohiko
    Sakurai, Shinichiro
    Suzuki, Akihiro
    Sawada, Hiroaki
    Sato, Shigeko
    Nishikawa, Yoshinori
    Amano, Tetsuya
    CIRCULATION, 2016, 134
  • [2] Inhibition of platelet aggregation by clopiclogrel is unaffected by the CYP2C19 681G>A polyrnorphism in patients with coronary artery disease
    Smith, Simon M. G.
    Buckland, Robert
    Daly, Martina E.
    Storey, Robert F.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 375A - 375A
  • [3] The Effect of CYP2C19 Genotype on the Time Course of Platelet Aggregation Inhibition After Clopidogrel Administration
    Kim, Ho-Sook
    Cho, Doo-Yeoun
    Park, Bo-Min
    Bae, Soo-Kyoung
    Yoon, Yune-Jung
    Oh, Minkyung
    Ghim, Jong-Lyul
    Kim, Eun-Young
    Kim, Dong-Hyun
    Shin, Jae-Gook
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (08): : 850 - 857
  • [4] The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel
    Tousoulis, Dimitris
    Siasos, Gerasimos
    Zaromitidou, Marina
    Oikonomou, Evangelos
    Maniatis, Konstantinos
    Kioufis, Stamatios
    Kokkou, Eleni
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (02) : 1594 - 1596
  • [5] Consistent and potent platelet inhibition of prasugrel irrespective of CYP2C19 polymorphism in Japanese patients with coronary artery disease
    Nishikawa, M.
    Isshiki, T.
    Ogawa, H.
    Kimura, T.
    Yokoi, H.
    Nanto, S.
    Takayama, M.
    Kitagawa, K.
    Miyazaki, S.
    Origasa, H.
    Sase, K.
    Umemura, K.
    Ikeda, Y.
    Yamaguchi, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 336 - 336
  • [6] Effects of CYP2C19 genotype on vascular function in patients with coronary artery disease receiving clopidogrel
    Zaromitidou, M.
    Tousoulis, D.
    Siasos, G.
    Kioufis, S.
    Oikonomou, E.
    Maniatis, K.
    Kokkou, E.
    Mazaris, S.
    Tourikis, P.
    Stefanadis, C.
    EUROPEAN HEART JOURNAL, 2013, 34 : 118 - 118
  • [7] The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease
    Peng, Yong
    Chen, Mao
    Liu, Xiao-jing
    Liu, Wei
    Li, Qiao
    Chai, Hua
    Ren, Xin
    Wang, Xue-qin
    Zhao, Zhen-gang
    Zhang, Chen
    Luo, Xiao-lin
    Huang, De-jia
    ATHEROSCLEROSIS, 2013, 227 (01) : 106 - 111
  • [8] Effects of CYP2C19 Genotype on Arterial Wall Properties in Patients with Coronary Artery Disease Receiving Clopidogrel
    Zaromitidou, Marina
    Tousoulis, Dimitris
    Siasos, Gerasimos
    Kioufis, Stamatios
    Oikonomou, Evangelos
    Maniatis, Konstantinos
    Miliou, Antigoni
    Gouliopoulos, Nikolaos
    Athanasiou, Dimitrios
    Dimitropoulos, Efstathios
    Vavuranakis, Manolis
    Aggeli, Constantina
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    CIRCULATION, 2012, 126 (21)
  • [9] Response to clopidogrel in patients with coronary artery disease is associated with CYP2C19 but not CYP2B6 genotype.
    Nystrom, P.
    Desta, Z.
    Jakubowski, J.
    Li, L.
    Hilligoss, J.
    Tisdale, J. E.
    Kreutz, Y.
    Miao, J.
    Flockhart, D. A.
    Kovacs, R.
    Jin, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S9 - S9
  • [10] Response to clopidogrel in patients with coronary artery disease is associated with CYP2C19 but not CYP2B6 genotype.
    Nystrom, P.
    Desta, Z.
    Jakubowski, J.
    Li, L.
    Hilligoss, J.
    Tisdale, J. E.
    Kreutz, Y.
    Miao, J.
    Flockhart, D. A.
    Kovacs, R.
    Jin, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S3 - S4
12345